【摘要】 目的:探讨促血小板生成素受体激动剂(海曲泊帕)是否可促进多发性骨髓瘤自体造血干细胞移植后血常规恢复。方法:回顾性分析2020年8月—2024年8月上海交通大学医学院附属新华医院血液科接受自体造血干细胞移植患者46例，其中16例干细胞回输后接受海曲泊帕治疗(治疗组),30例未接受海曲泊帕治疗(对照组)。比较两组基线资料及血细胞恢复情况。结果:治疗组与对照组之间，基线资料(年龄、体能状态、美法仑剂量、移植前缓解状态、回输干细胞数量等)差异无统计学意义，治疗组血小板恢复时间为(10.38±1.46) d,明显短于对照组(12.30±1.75) d(P<0.01),回输后第14天血小板计数水平治疗组明显高于对照组[(56.38±25.12)×10~9/L vs (44.03±15.39)×10~9/L,P=0.044]。多因素线性回归分析发现，使用促血小板生成素受体激动剂会促进血小板植入(P<0.01)。结论:促血小板生成素受体激动剂(海曲泊帕)可能促进多发性骨髓瘤患者自体造血干细胞移植后血小板植入。更多还原

【Abstract】 Objective: To investigate whether the thrombopoietin receptor agonist(hetrombopag) can promote blood count recovery after autologous hematopoietic stem cell transplantation in multiple myeloma. Methods: A retrospective analysis was conducted on 46 patients who underwent autologous hematopoietic stem cell transplantation in the hematology department of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from August 2020 to August 2024. Among them, 16 patients received treatment with hetrombopag after stem cell transfusion(treatment group), and 30 patients did not receive treatment with hetrombopag(control group). We compared baseline data and blood cell recovery between two groups. Results: There was no significant difference in baseline data between the treatment group and the control group, including age, physical fitness status, melphalan dosage, pre-transplant remission status, and number of reinfused stem cells. The platelet recovery time in the treatment group was(10.38±1.46) d, which was significantly shorter than that in the control group at(12.30±1.75) d(P<0.01). On the 14th day after reinfusion, the platelet level in the treatment group was significantly higher than that in the control group[(56.38±25.12)×10~9/L vs(44.03±15.39)×10~9/L, P=0.044]. Multivariate linear regression analysis found that the use of thrombopoietin receptor agonists promotes platelet implantation(P<0.01). Conclusion: Thrombopoietin receptor agonists(hetrombopag) may promote platelet implantation in patients with multiple myeloma after autologous hematopoietic stem cell transplantation.更多还原